www.stirlingproducts.net
Stirling Products (ASX:STI) is a manufacturer and marketer of proprietary and/or patented pharmaceutical products and natural health products for its own interests as well as on a contractual basis for third parties. Strategically, Stirling Products is positioned to capitalise on the rapidly changing conditions within the global pharmaceutical and health markets.
The Stirling Products corporate headquarters are in Sydney, Australia and its North American pharmaceutical manufacturing operations are based on Cape Breton, Nova Scotia, Canada.
Stirling operates through three main business units each managed by proven industry specialist managers:
- Pharmaceutical & Healthcare
- Research & Development
- Animal Products
Stirling Products expects to be granted TeleMedCare rights within six months
Stirling Products (ASX: STI) expects the rights for use for its TeleMedCare (TMC) system to be granted within six months for several high profile markets.
The company is currently negotiating rights for use in the USA, Canada, Sweden, Russia and India and is looking to realise these and potentially others during the course of 2011.
TMC provides the only viable multi-user vital signs monitoring service/device in the world and has attracted interest from a number of major corporations.
The TMC system delivers sophisticated health management in multi-user clinical and community settings, as well as medications management systems in residential care facilities.
Stirling is aggressively pursuing license and partnership relationships with majors and recently appointed ex IBM UK Commercial Director, John Botten, to develop these relationships.
In relation to this aim, a recent citation and recommendation through Microsoft’s Health Vault and Industry White Paper earlier this year praised the company for its range of devices and services for the home care, nursing and chronic disease markets.
The paper stated that “we can certainly help this company through our established partner program resources and provide them with a little more exposure on the world stage,” highlighting the potential of Stirling Products.
The TMC Multi-User Clinical Monitoring carries a CE mark (UK, EU) and the Australian Department of Health and Aging Therapeutic Goods Administration (TGA) certification.
On April 18 Stirling began manufacturing operations at its high-tech pharmaceutical plant in Cape Breton, Nova Scotia, enabling production and cash flows to come on stream.
Stirling reported having $447,000 in cash at the end of the last quarter, up from $113,000 from the beginning of the quarter.


















